Neuralstem (CUR) Surges on FDA Approval To Start First ALS Stem Cell Trial
Tweet Send to a Friend
Shares of Neuralstem, Inc. (NYSE: CUR) are up 60% after the company announced that the FDA has approved its Investigational ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
